Skip to main content
. Author manuscript; available in PMC: 2021 Jun 4.
Published in final edited form as: Cancer Discov. 2020 Jan 8;10(3):394–405. doi: 10.1158/2159-8290.CD-19-1130

Figure 2.

Figure 2.

T cells, monocytes, and NK cell counts in peripheral blood from all acalabrutinib-treated patients over time. Absolute counts of CD4+ (A) and CD8+ (B) T cells, CD14+ monocytes (C), and NK cells (CD16+CD56+; D). Cells were measured by flow cytometry. The normal reference range for each subset is shown with dashed lines. All plots include patients being assessed at baseline assessment and the respective visit. P values are from the Wilcoxon signed-rank test. NK, natural killer.